Physician profile

Albert Hoffman

Optometrist · Conneaut, OH

NPI 1346422417

$300.05

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$136.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bausch & Lomb Americas INC. $106.81 2022-2023 Vyzulta, Lotemax Sm, Infuse
Glaukos Corporation $65.97 2021
Abbvie INC. $39.96 2023-2024
Optos, INC. $24.50 2019
Abb Con-Cise Optical Group LLC $20.25 2024 Contact Lens, Spectacle Lenses
Thea Pharma INC. $16.81 2024 Iyuzeh
Aerie Pharmaceuticals, INC. $14.61 2019
Allergan, INC. $11.14 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Albert Hoffman

$300.05

in general payments reported 2019-2025

Years
2019-2024
Top company
Bausch & Lomb Americas INC.

https://glasscript.com/doctor/715179/albert-hoffman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.